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Abstract
Background: Hypomethylation of Long Interspersed Nucleotide Element-1 (LINE-1) is associated with worse
prognosis in colorectal cancer (CRC). However, little is known about the relevance of this marker for the prognosis
and response to chemotherapy of metastatic and recurrent (advanced-stage) CRC. Our aim was therefore to
investigate whether tumor LINE-1 hypomethylation correlates with patient survival and with response to 5-
fluorouracil (5-FU)/ oxaliplatin (FOLFOX) chemotherapy in advanced-stage CRC.
Methods: The study included 40 CRC patients who developed metastasis or local recurrence after surgery and
subsequently underwent FOLFOX therapy. Progression-free and overall survival were estimated using the Kaplan-
Meier method. LINE-1 methylation levels in formalin-fixed and paraffin-embedded primary tumor tissues were
measured by MethyLight assay and correlated with patient survival. In vitro analyses were also conducted with
human colon cancer cell lines having different LINE-1 methylation levels to examine the effects of 5-FU and
oxaliplatin on LINE-1 activity and DNA double-strand-breaks.
Results: Patients with LINE-1 hypomethylation showed significantly worse progression-free (median: 6.6 vs 9.4 months;
P = 0.02) and overall (median: 16.6 vs 23.2 months; P = 0.01) survival following chemotherapy compared to patients
with high methylation. LINE-1 hypomethylation was an independent factor for poor prognosis (P = 0.018) and was
associated with a trend for non-response to FOLFOX chemotherapy. In vitro analysis showed that oxaliplatin increased
the LINE-1 score in LINE-1-expressing (hypomethylated) cancer cells, thereby enhancing and prolonging the effect of 5-
FU against these cells. This finding supports the observed correlation between tumor LINE-1 methylation and response
to chemotherapy in CRC patients.
Conclusions: Tumor LINE-1 hypomethylation is an independent marker of poor prognosis in advanced-stage CRC and
may also predict non-response to combination FOLFOX chemotherapy. Prospective studies are needed to optimize the
measurement of tumor LINE-1 methylation and to confirm its clinical impact, particularly as a predictive marker.
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Background
Colorectal cancer (CRC) is one of the most common can-
cer types worldwide and was responsible for an estimated
694,000 deaths in 2012 [1]. Although the incidence of
CRC is increasing, mortality from CRC has decreased in
many countries [1]. This trend is likely due to early diag-
nosis and the development of multidisciplinary treatments
[2]. Chemotherapy with 5-fluorouracil (5-FU) has been
the key drug for the last 50 years. Untreated patients with
metastatic CRC have a median survival period of only
8 months, whereas this is prolonged to 16.2–19.5 months
by treatment with 5-FU and leucovorin in combination
with oxaliplatin or irinotecan [3, 4].
Aberrant hypermethylation of tumor DNA is thought
to contribute to the development and progression of
cancer, including CRC, by silencing the expression of
tumor suppressor genes [5]. On the other hand,
genome-wide hypomethylation of tumor DNA induces
genomic instability by reactivating transposable DNA se-
quences and this change has also been associated with
colorectal carcinogenesis [6–8]. Emerging evidence indi-
cates that epigenetic mechanisms such as aberrant DNA
methylation can trigger resistance to 5-FU, oxaliplatin
and irinotecan in CRC [9]. Oxaliplatin exerts its cyto-
toxic effects via DNA damage and the arrest of nucleic
acid synthesis [10]. The different mechanisms of resist-
ance to oxaliplatin include histone methylation and vari-
ous gene alterations. However, the most important
mechanism appears to involve the DNA mismatch repair
(MMR) and nucleotide excision repair (NER) systems
[11, 12]. Although tumor DNA hypermethylation has
been implicated in chemoresistance [13, 14], little is
known about its relationship to oxaliplatin resistance.
Long interspersed nucleotide element-1 (LINE-1) is
one of the retrotransposons that are distributed through-
out the genome. LINE-1 is about 6 kb long, occupies ap-
proximately 18% of the genome and plays a role in
regulating genomic structure and function [15, 16]. Its
insertion into gene promoters and exons results in the
functional disruption of these sequences, while its inser-
tion into introns causes exon skipping, alternative spli-
cing and transcriptional attenuation [17]. Because of the
high frequency of LINE-1 in the genome, its hypomethy-
lation provides an accurate representation of global
DNA hypomethylation [8, 18]. Tumor LINE-1 hypome-
thylation has consistently been associated with worse
survival in CRC patients [19–21]. We also reported earl-
ier that LINE-1 hypomethylation was predictive of good
response to oral fluoropyrimidines in the adjuvant set-
ting [22] and that LINE-1 methylation levels in primary
tumors correlated well with those of metastatic lesions
from the same patient [23, 24]. Recently, the predictive
and prognostic significance of LINE-1 hypomethylation
has been studied by several independent groups in
metastatic (Stage IV) CRC using large patient cohorts
[25, 26]. Furthermore, the potential association of LINE-
1 hypomethylation with therapeutic efficacy of FOLFOX
(combined folate, 5-fluorouracil and oxaliplatin) regimen
has also been reported [27]. However, so far there are no
systemic studies on the prognostic and predictive signifi-
cance of LINE-1 hypomethylation in metastatic CRC pa-
tients who undergo treatment with FOLFOX. The aim
of the present study was therefore to determine whether
the level of LINE-1 methylation in the primary tumor of
advanced-stage CRC patients was associated with overall
survival and with response to FOLFOX combination
chemotherapy. We also investigated whether LINE-1
methylation levels in colon cancer cell lines were associ-
ated with sensitivity to 5-FU or oxaliplatin.
Methods
CRC patients and tissue samples
This study included 40 patients with CRC who under-
went surgery between October 1999 and November
2010 at the Ishikawa Prefectural Central Hospital (clin-
ical details shown in Table 1). Surgical specimens includ-
ing primary tumor were fixed by neutralized formalin and
embedded in paraffin for routine histopathology diagnosis.
Between 2005 and 2011, patients who developed metasta-
sis or unresectable local recurrence after surgery were
treated with a FOLFOX regimen consisting of bolus intra-
venous injection with oxaliplatin (85 mg/m2), leucovorin
(200 mg/m2) and 5-FU (400 mg/m2), followed by continu-
ous infusion over 46 h with 5-FU (2,400 mg/m2) [28]. This
regimen was repeated every 2 weeks until disease progres-
sion or the occurrence of intolerable toxicities. Response
to the FOLFOX regimen was evaluated over 4 to 6 courses
of treatment according to the Response Evaluation Cri-
teria in Solid Tumors (RECIST version 1.1) [29]. None of
the patients received 5-FU-based chemotherapy before
primary surgery. Progression-free survival (PFS), overall
survival (OS) and 5-year overall probability of survival
(OPS) were all defined from the time of initiation of
chemotherapy.
Tumor tissue was identified in representative 10 μm-
thick paraffin sections. Following deparaffinization the
genomic DNA was isolated using QIAamp DNA mini
kits (Qiagen, Hilden, Germany).
Colon cancer cell lines
Colon cancer cell lines SW480, HCT116, Caco-2 and
RKO were obtained from the American Type Culture Col-
lection (Manassas, VA, USA). The cells were maintained
at 37 °C with 5% CO2 in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine
serum and antibiotics (100 units/mL penicillin G, 100 μg/
mL streptomycin; Gibco, Grand Island, NY, USA).
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Drug treatment of cells
We determined the concentration of oxaliplatin (2 μM)
for the treatment of colon cancer cells by reference to
the reported IC50 (concentration resulting in 50% growth
inhibition) [30]. The concentration of 5-FU (1 or 2 μM)
was determined in our previous study [22]. Cells were
cultured for 24 h and then treated with oxaliplatin for
2 h. Following replacement of the medium, cells were
treated with 5-FU for 48 h or 120 h. The effects of drug
treatment were examined by measuring LINE-1 activity
and DNA double-strand breaks as described below.
LINE-1 methylation analysis
Genomic DNA was extracted from formalin-fixed and
paraffin-embedded (FFPE) tumor tissues and cultured
cells and treated with bisulfite using the EpiTect Plus
Bisulfite Conversion kit (QIAGEN). LINE-1 methylation in
CRC tumor tissues was measured by using the MethyLight
assay as described previously [31]. LINE-1 methylation in
CRC cell lines was quantified using methylation-specific
real-time PCR [32] with the ABI-PRISM 7900 Sequence
Detection System (Applied Biosystems, Osaka, Japan) and
Premix Ex Taq (TaKaRa Bio, Otsu, Japan). The primers and
probes used for LINE-1 methylation analyses [23, 32] were
shown in Additional file 1: Table S1 and Additional file 2:
Figure S1. The level of LINE-1 methylation was expressed
as a median value with 25th–75th percentile. LINE-1
methylation levels for the colon cancer cells used in this
study were determined in our previous study [22].
Formaldehyde-assisted isolation of regulatory elements
(FAIRE)
FAIRE isolates DNA regions with active chromatin and
therefore enriches in functional genomic elements such as
active promoters and transcriptional start sites. This was
performed as described earlier [33] to enrich and measure
the active promoter of LINE-1 in colon cancer cells. It is
reported that DNA without histone binding isolated by
FAIRE is active in retrotransposons including LINE-1
[34]. Following treatment of cells with 1% formaldehyde
for 5 min, glycine was added to a final concentration of
125 mM for 5 min. The cross-linked chromatin was
sheared by sonication and this was followed by phenol-
chloroform extraction. Covalently linked protein-DNA
complexes were sequestered into the organic phase, leav-
ing protein-free DNA fragments in the aqueous phase.
The DNA was precipitated by incubation with sodium
acetate, glycogen and ethanol at −20 °C overnight. The
amount of LINE-1 was measured by quantitative real-time
PCR as described above and the LINE-1 score was ob-
tained using the ΔΔCt method. Design of the primers
used for the real-time PCR was shown in Additional file 1:
Table S1 and Additional file 2: Figure S1.
Measurement of phospho-histone H2A.X (γH2A.X) foci
Cells were plated onto coverslips for 24 h prior to treat-
ment with drugs as described above. Following treat-
ment, cells were fixed in 4% paraformaldehyde for
10 min at room temperature and permeabilized for
5 min in 0.2% Triton X-100. After blocking with 5%
skim milk for 60 min, cells were incubated with antibody
to γH2A.X (Millipore, Darmstadt, Germany) for 90 min
at 37 °C. The cells were then incubated with secondary
antibody (CyTM3-conjugated AffiniPure F(ab’)2 Fragment
Goat Anti-Mouse IgG(H + L), Molecular Probes, Eugene,
Oregon, USA) for 60 min at 37 °C. Immunostained cells
were observed by fluorescence microscopy in order to
score γH2A.X foci.
Table 1 Association between the tumor LINE-1 methylation
levels and clinicopathological characteristics of the advanced-
stage CRC patients
n LINE-1 methylation p-value
Gender
Male 26 46.8 (39.8–53.2) 0.738
Female 15 48.5 (43.6–53.0)
Age (years)
65≥ 20 47.4 (43.1–51.7) 0.806
>65 21 47.4 (41.4–52.6)
Sites of primary tumors
Colon 25 47.2 (42.2–51.7) 0.517
Rectum 16 47.7 (43.0–54.2)
Tumor histological types
Well-differentiated 4 47.6 (45.6–52.9) 0.941
Moderately-differentiated 34 47.5 (42.5–53.2)
Poorly-differentiated 3 46.7 (41.5–52.9)
Status
Advanced (stage IV) 18 45 (42.1–48.9) 0.113
Recurrence 23 49.3 (43.3–54.4)
Distant metastasis
One organ 29 48.4 (43.8–54.0) 0.185
Multiple organs 12 45 (40.7–51.4)
Previous treatment with 5-FU
Yes 22 48.8 (42.5–53.2) 0.429
No 19 45.8 (42.6–51.7)
Number of previous regimens
0 30 46.8 (43.5–52.3) 0.612
1 11 49.1 (40.1–55.8)
LINE-1 methylation levels are shown as the median value (25th–75th
percentile). Histological type of the primary tumor was classified into well-,
moderately- and poorly-differentiated adenocarcinoma according to their
grading. 5-FU, 5-fluorouracil; LINE-1, long interspersed nucleotide element-1; n,
number of patients
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Statistical analysis
Mann–Whitney U-test, Kruskal-Wallis or Fisher’s exact
test were used to compare LINE-1 methylation levels be-
tween variables. A receiver operating characteristic
(ROC) curve was created to evaluate the threshold of
LINE-1 methylation level. Kaplan-Meier analysis and the
log-rank test were used to evaluate differences in
survival between patient groups. The prognostic signifi-
cance of multiple variables was evaluated using a Cox
proportional hazard regression model. Scores for
γH2A.X foci were compared by Mann–Whitney U-test.
All P-values shown are two-tailed, with P < 0.05 taken as
significant. All statistical analyses were performed with
EZR (Saitama Medical Center, Jichi Medical University,
Saitama, Japan), which is a graphical user interface for R
(The R Foundation for Statistical Computing, Vienna,
Austria, version 3.1.2). It is a modified version of R
commander (version 2.1-5) designed to add statistical
functions that are frequently used in biostatistics [35].
Results
Tumor LINE-1 hypomethylation correlated with poor
response to FOLFOX and with worse survival of
advanced-stage CRC patients
LINE-1 methylation (median; 25th–75th percentile) in
the primary tumor of advanced-stage CRC patients
(47.4%; 42.2–53.5%) (Fig. 1; Additional file 3: Figure
S2A) was lower than in our previous study [22] of stage
II and III CRC (84.7%; 27.8–94.0%). None of the patients
in the present series was categorized as being in the high
LINE-1 methylation (>84.3%) group defined in our pre-
vious study [22]. No significant associations were found
between LINE-1 methylation and clinicopathological
characteristics including age, sex, primary tumor site,
metastatic sites and prior treatment with 5-FU
(Table 1). Higher LINE-1 methylation levels were as-
sociated with a trend for better clinical response to
FOLFOX chemotherapy (Fig. 2; Additional file 3:
Figure S2B), however this did not reach statistical
significance (P = 0.18).
An ROC curve was constructed to assess response
(complete response, partial response and stable dis-
ease) or no response (progressive disease) to FOLFOX
chemotherapy according to tumor LINE-1 methylation
(Fig. 3a). The cutoff value for LINE-1 methylation
level was 51.7%, as determined by the point yielding
the greatest sum for sensitivity and specificity. The
area under the curve (AUC) was 0.67 (95% CI: 0.49–
0.85). Tumor LINE-1 methylation levels were thus
classified as high (n = 14) or low (n = 27) according to
this cutoff value. No significant differences in clinical
and histopathological characteristics were apparent
between the high and low LINE-1 methylation patient
groups (Additional file 4: Table S2). However, the
PFS, OS and 5-year OPS were significantly worse in
the low compared to high methylation group (PFS:
median 6.6 vs. 9.4 months, P = 0.02; OS: median 16.6
vs. 23.2 months, P = 0.01; 5-year OPS: 4.1% vs. 28.6%)
(Fig. 3b, c). Multivariate analysis by COX proportional
hazard model demonstrated that LINE-1 hyp-
omethylation was an independent factor for poor
prognosis (P = 0.018; Table 2, Additional file 5: Table
S3, Additional file 6: Figure S3).





















Fig. 1 Distribution of LINE-1 methylation level in the primary tumors
of advanced-stage CRC. The median level of LINE-1 methylation
was 47.4%
Best  overall response



















Fig. 2 Tumor LINE-1 methylation levels in CRC patient groups
classified according to their best overall response. LINE-1
methylation levels are shown as the median and 25th–75th
percentile. CR, complete remission; PR, partial remission; SD,
stable disease; PD, progressive disease
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Effects of oxaliplatin on LINE-1 activity and DNA damage
in colon cancer cells
It was previously reported that SW480 and Caco2 cells
show low LINE-1 methylation (55%) and express LINE-
1, whereas HCT116 and RKO cells have higher LINE-1
methylation (65–90%) and express little or no LINE-1
[22, 36]. The effect of oxaliplatin on DNA stability in
colon cancer cells with different levels of LINE-1 methyla-
tion was examined here using FAIRE. The baseline score
for LINE-1 activity was higher in SW480 cells compared
to HCT116, RKO and Caco2 cells, although the latter cell
line also expressed LINE-1 (Fig. 4a; Additional file 7:
Figure S4). Treatment of cells with 2 μM oxaliplatin for
2 h decreased the LINE-1 score in HCT116 and RKO, but
not in SW480 and Caco2 cells. This suggests that oxalipla-
tin stabilizes the DNA of colon cancer cells with high
LINE-1 methylation by attenuating LINE-1 transposition
activity.
Next, the level of DNA damage in cells following treat-
ment with oxaliplatin was evaluated by scoring the num-
ber of γH2A.X foci. This value reflects the extent of DNA
double-strand breaks. In the untreated condition, γH2A.X
foci (median; range) were more frequently (P < 0.01)
detected in LINE-1-expressing SW480 (3.37; 0–20) and
Caco2 cells (4.89; 0–40) than in LINE-1-non-expressing
HCT116 (1.90; 0–20) and RKO cells (0.64; 0–12) (Fig. 4b).
Treatment with 2 μM oxaliplatin for 2 h increased the
number of foci in all cell lines. The effect of oxaliplatin on
SW480 and HCT116 cells was monitored for 2 h, 48 h
and 120 h. While the number of γH2A.X foci in SW480
cells increased progressively following treatment with oxa-
liplatin, the effect was transient in HCT116 (Fig. 4c).
These results suggest the DNA in LINE-1-expressing cells
such as SW480 is unstable and that treatment with oxali-
platin reinforces the DNA damage for an extended period
over 120 h.
Combined effect of oxaliplatin and 5-FU on colon cancer
cells
The combined effect of oxaliplatin and 5-FU on DNA
double-strand breaks was compared in LINE-1-expressing
(SW480) and non-expressing (HCT116) cells (Fig. 5,
Additional file 8: Figure S5). In SW480 cells, treatment
with 2 μM 5-FU alone for 48 h increased the number of
γH2A.X foci 1.28-fold compared to untreated cells. Pre-
treatment of SW480 cells with 2 μM oxaliplatin en-
hanced the effect of 5-FU between 1.49- and 1.92-
fold and this effect persisted for up to 120 h. In
HCT116 cells, treatment with 2 μM 5-FU alone for
48 h increased the number of γH2A.X foci 4.26-fold
compared to untreated cells (P < 0.0005). Pretreatment
of HCT116 cells with 2 μM oxaliplatin enhanced the ef-
fect of 5-FU by 7.16-fold (P < 0.0005), but no combined ef-
fect was found at 120 h after treatment. These results
a
P=0.025
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Fig. 3 Comparison of tumor LINE-1 methylation levels with the survival
of advanced-stage CRC patients. a ROC curve was constructed
according to response (CR, PR and SD) or no response (PD) to
the FOLFOX regimen. The cut-off value was determined as the point
yielding the greatest sum of sensitivity and specificity for prediction of
outcome. b, c Kaplan-Meier analysis of progression-free and overall
survival of patient groups stratified according to their tumor LINE-1
methylation level. The log-rank test was used for each comparison and
p-values are shown
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indicate that the effects of sequential treatment with oxali-
platin and 5-FU, which mimic the clinically used FOLFOX
regimen, depend on the level of LINE-1 methylation in
colon cancer cells.
Discussion
Several previous studies have reported an association
between tumor LINE-1 hypomethylation and worse
survival of CRC patients from different clinical stages
[19–21, 25–27]. We have also reported that 5-FU-based
adjuvant chemotherapy appeared to benefit stage II and
III CRC patients with low tumor LINE-1 methylation,
but not those with high methylation [22]. In the present
study we investigated LINE-1 methylation in the primary
tumors of CRC patients with distant metastasis and/or
recurrent tumors. We evaluated the prognostic relevance
(PFS, OS, 5-year OPS) of LINE-1 methylation in patients
who received chemotherapy with the combined oxalipla-
tin and 5-FU (FOLFOX) regimen. In agreement with the
earlier studies cited above, tumor LINE-1 hypomethyla-
tion (i.e. below the cutoff value of 51.7% determined by
ROC analysis) was associated with worse patient survival
(Fig. 3b, c). In multivariate analysis, LINE-1 hypomethy-
lation was shown to be an independent prognostic factor
Table 2 Multivariate analysis for prognostic significance of clinicopathologic factors and tumor LINE-1 methylation in metastatic CRC
Variables Hazard ratio (95% CI) p-value
Female 0.85 (0.38–1.91) 0.70
Older patientsa 0.63 (0.28–1.41) 0.26
Rectum (vs. colon) 0.84 (0.38–1.85) 0.66
Well differentiation (vs. others) 0.95 (0.26–3.41) 0.94
Recurrence (vs. stage IV) 0.81 (0.31–2.14) 0.67
Multiple organs (vs. one organ) metastasis 0.85 (0.34–2.08) 0.72
Previous treatment with 5-FU 1.62 (0.55–4.77) 0.38
Second line (vs. first line) chemotherapy 1.08 (0.37–3.11) 0.89
LINE-1 hypomethylation b 2.74 (1.19–6.29) 0.018
aAge: older (>65 y) versus younger (65 y ≥) patients
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Fig. 4 Effects of oxaliplatin on LINE-1 activity and γH2A.X foci in colon cancer cell lines. a Comparison of LINE-1 scores determined by FAIRE in
LINE-1-expressing (SW480, Caco2) and non-expressing (HCT116, RKO) colon cancer cells that were treated with or without 2 μM oxaliplatin for
2 h. b Comparison of γH2A.X foci in colon cancer cells treated with or without 2 μM oxaliplatin for 2 h. c Comparison of γH2A.X foci between
SW480 and HCT116 cells treated with or without 2 μM oxaliplatin for 2, 48 and 120 h, respectively
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in advanced-stage CRC. The significant difference in sur-
vival between patients with high and low tumor LINE-1
methylation levels, together with the trend for inverse
association between response to chemotherapy and
LINE-1 methylation (Fig. 2), suggest this marker could
help to select advanced-stage CRC patients who may
benefit from FOLFOX.
We previously reported that stage II and III CRC pa-
tients with high LINE-1 methylation in their primary
tumor did not show a survival benefit from adjuvant
chemotherapy with oral 5-FU [22]. This apparent discrep-
ancy with the current results from advanced stage CRC
patients may be due to the different stages of the patient
cohorts, the different chemotherapy regimen used, as well
as the different cutoff values used to define high and low
LINE-1 methylation levels. In previous studies, LINE-1
methylation levels were divided into the three categories
of high, intermediate and low [22, 37, 38]. In our earlier
study [22], patients defined as having “high” (≥84%)
methylation showed favorable prognosis but little re-
sponse to oral 5-FU chemotherapy. The “intermediate”
(52–84%) and “low” (<52%) methylation tumor groups are
susceptible to metastasis, while the former group is sensi-
tive but the latter insensitive to 5-FU-based chemother-
apy. According to this categorization and based on the
cutoff value (51.7%) determined by the current ROC ana-
lysis (Fig. 3a), patients with high LINE-1 methylation as
defined in the present study are included in the “inter-
mediate” methylation group and there were no patients
showing “high” methylation as defined above (≥84%). This
could explain why patients with higher LINE-1 methyla-
tion (≥51.7%) showed better outcome following FOLFOX
treatment compared to those with lower LINE-1 methyla-
tion (<51.7%). Consistent with previous studies [37, 38],
patients with low LINE-1 methylation responded poorly
to FOLFOX. Aside from the different CRC clinical stages
and chemotherapy regimens, the difference in cutoff value
for LINE-1 methylation (84.3% vs. 51.7%) between our
previous [22] and present study does not allow direct
comparison of the predictive value of LINE-1 methylation
for response to 5-FU-based chemotherapy.
Previous [22, 37, 38] and present studies used DNA ex-
tracted from FFPE tumor tissues for bisulfite conversion
and subsequent measurement of LINE-1 methylation. This
may raise concern whether formalin fixation-associated
DNA crosslinking and degradation will confound the quan-
titative PCR-based analysis of LINE-1 methylation. There-
fore, this issue should be carefully addressed for clinical




































Fig. 5 Combined effect of oxaliplatin and 5-FU treatment on LINE-1 expressing and non-expressing colon cancer cells. SW480 (LINE-1 expressing)
and HCT116 (LINE-1 non-expressing) cells were treated with oxaliplatin (2 μM) alone, 5-FU (1 μM, 2 μM) alone, or a combination of both.
For the combined treatment, the respective cells were treated sequentially with 2 μM oxaliplatin for 2 h and then with 5-FU (1 μM or
2 μM) for 48 h and 120 h. γH2A.X foci were measured following the respective treatments. Statistical differences between the data are
shown in Additional file 4: Figure S2
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To investigate putative mechanistic links between
tumor LINE-1 methylation and therapeutic effects of the
FOLFOX regimen, we examined human colon cancer
cell lines with different LINE-1 methylation and expres-
sion levels. DNA double-strand breaks were induced by
sequential combination treatment with oxaliplatin and
5-FU, thus mimicking the clinical FOLFOX regimen.
The DNA damaging effect of this combined treatment
was more marked and persistent in LINE-1-expressing
SW480 cells (lower methylation) compared to HCT116
cells with no LINE-1 expression (higher methylation;
Fig. 4c). This observation is consistent with previous re-
ports that the DNA of LINE-1-expressing cancer cells is
unstable due to its retrotransposition ability and is there-
fore inherently susceptible to cytotoxic insults [7, 8].
However, there is no direct evidence suggesting the cor-
relation between LINE-1 expression and genomic in-
stability. The different γH2A.X activity in different cell
lines may be attributed to other sources such as intrinsic
resistance (e.g., the ability of drug efflux) or the activities
of DNA damage sensing and repair. The therapeutic ef-
fect observed in these colon cancer cells (Fig. 5) is in-
consistent with the difference in outcome between
advanced-stage CRC patients with high and low LINE-1
methylation levels treated with FOLFOX (Fig. 3). To
address this discrepancy between clinical and in vitro
findings, further investigations including verification of
FFPE tissue samples as discussed above are needed on
the expression of other known predictive biomarkers in
experimental and clinical settings of combined ox-
aliplatin/5-FU regimens. These include the expression of
thymidylate synthase [9] and dihydropyrimidine de-
hydrogenase [39] for 5-FU and excision-repair cross-
complementing-1 for oxaliplatin [10].
Methylation of genes other than LINE-1, including
hMLH1, TFAP2E and SPARC, have been associated with
resistance to chemotherapy [14, 40–42]. Based on such
findings, a phase I clinical trial was undertaken to test
the safety and efficacy of azacitidine, a demethylating
agent, in combination with oxaliplatin for patients with
advanced cancers (including CRC) that had relapsed or
were refractory to any platinum therapy [13].
Conclusions
We have demonstrated that tumor LINE-1 hypomethyla-
tion is an independent marker of poor prognosis in
advanced-stage CRC and may also be predictive of non-
response to combination oxaliplatin/5-FU chemotherapy.
Further prospective studies are required to establish
whether tumor LINE-1 methylation can be a clinically
useful prognostic and predictive biomarker for 5-FU-
based chemotherapy in CRC patients. A critical issue will
be to standardize the method for measuring tumor LINE-
1 methylation level and for determining the cutoff value.
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Additional file 6: Figure S3. Influence of clinical and histopathological
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